Vontobel Holding Ltd. Acquires 394,567 Shares of Gilead Sciences, Inc. $GILD

Vontobel Holding Ltd. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 192.2% during the 3rd quarter, Holdings Channel.com reports. The firm owned 599,860 shares of the biopharmaceutical company’s stock after buying an additional 394,567 shares during the quarter. Vontobel Holding Ltd.’s holdings in Gilead Sciences were worth $66,584,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Rothschild Investment LLC boosted its position in Gilead Sciences by 1.9% during the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after buying an additional 84 shares during the period. Ignite Planners LLC lifted its stake in shares of Gilead Sciences by 1.1% in the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after acquiring an additional 86 shares during the last quarter. Archer Investment Corp lifted its stake in shares of Gilead Sciences by 1.2% in the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock valued at $807,000 after acquiring an additional 87 shares during the last quarter. Binnacle Investments Inc boosted its holdings in Gilead Sciences by 14.3% during the 2nd quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 88 shares during the period. Finally, EPG Wealth Management LLC grew its position in Gilead Sciences by 2.0% during the 2nd quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock worth $513,000 after acquiring an additional 89 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of several recent research reports. Wall Street Zen downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Needham & Company LLC upped their price target on shares of Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Wolfe Research reissued an “outperform” rating and set a $150.00 price target on shares of Gilead Sciences in a research report on Monday, December 15th. Citigroup raised their price target on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Wednesday, October 8th. Finally, The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $131.54.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $125.19 on Wednesday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The firm’s fifty day simple moving average is $122.61 and its 200 day simple moving average is $116.40. The stock has a market cap of $155.32 billion, a P/E ratio of 19.41, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period in the prior year, the business earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,805 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $127.10, for a total transaction of $356,515.50. Following the transaction, the director owned 1,339 shares in the company, valued at approximately $170,186.90. This represents a 67.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $122.00, for a total value of $366,000.00. Following the completion of the transaction, the insider directly owned 106,221 shares of the company’s stock, valued at $12,958,962. This represents a 2.75% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 136,257 shares of company stock worth $16,723,492. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.